KBS - Pharmaceutical Consultancy and Life Sciences - Market Insight

WHICH FACTORS DRIVE GROWTH IN THE UK PHARMA CONSULTANCY AND LIFE SCIENCES INDUSTRY?

Several key factors are expected to drive growth in the UK pharmaceutical consultancy and life sciences industry. These include:

+ RESEARCH AND DEVELOPMENT INVESTMENTS With substantial R&D budgets, the life sciences sector continues to thrive. Companies in the UK invested £9billion in pharmaceutical R&D in 2022, accounting for 18% of all business R&D. + GOVERNMENT SUPPORT AND FUNDING The UK government has committed significant funding, such as the £1billion investment in the life sciences sector and an additional £1.6billion to improve NHS services. + REGULATORY ENVIRONMENT Post-Brexit regulatory changes are promoting a more dynamic landscape for pharmaceutical companies. Companies must now obtain approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), enhancing compliance and potentially fostering more significant innovation. + EMERGENCE OF MEDTECH A £200million investment by the UK government in the MedTech sector, particularly focusing on data digitisation, is set to boost innovation and commercialisation efforts. + GLOBAL DEMAND Increasing purchasing power in developing economies, coupled with ageing populations in developed ones, continues to drive the demand for pharmaceuticals and life sciences products globally.

These initiatives and investments are driving considerable progress and growth, positioning the UK as a leader in pharmaceutical and life sciences innovation.

Companies in the UK invested £9billion in pharmaceutical R&D in 2022, accounting for 18% of all business R&D.